RU2018102374A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018102374A3 RU2018102374A3 RU2018102374A RU2018102374A RU2018102374A3 RU 2018102374 A3 RU2018102374 A3 RU 2018102374A3 RU 2018102374 A RU2018102374 A RU 2018102374A RU 2018102374 A RU2018102374 A RU 2018102374A RU 2018102374 A3 RU2018102374 A3 RU 2018102374A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168495 | 2011-06-01 | ||
| EP11168495.7 | 2011-06-01 | ||
| EP11173588.2 | 2011-07-12 | ||
| EP11173588 | 2011-07-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013157300A Division RU2644346C2 (ru) | 2011-06-01 | 2012-06-01 | Система полицистронной экспрессии для бактерий |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018102374A RU2018102374A (ru) | 2019-02-21 |
| RU2018102374A3 true RU2018102374A3 (cg-RX-API-DMAC7.html) | 2021-03-30 |
| RU2766157C2 RU2766157C2 (ru) | 2022-02-08 |
Family
ID=46354175
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018102374A RU2766157C2 (ru) | 2011-06-01 | 2012-06-01 | Система полицистронной экспрессии для бактерий |
| RU2013157300A RU2644346C2 (ru) | 2011-06-01 | 2012-06-01 | Система полицистронной экспрессии для бактерий |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013157300A RU2644346C2 (ru) | 2011-06-01 | 2012-06-01 | Система полицистронной экспрессии для бактерий |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9920324B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3360967B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6175428B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102066292B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN103562390B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2012264589B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013030824A8 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3136084A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2714912T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2676877T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE039577T2 (cg-RX-API-DMAC7.html) |
| RU (2) | RU2766157C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012164083A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2714912T3 (en) | 2011-06-01 | 2018-08-13 | Intrexon Actobiotics Nv | POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA |
| US9593339B1 (en) * | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
| EP3034610A1 (en) * | 2013-08-13 | 2016-06-22 | The Kitasato Institute | Novel terpenoid compound and method for producing same |
| CA2969100C (en) * | 2014-12-03 | 2023-03-21 | Anaeropharma Science, Inc. | Coexpression plasmid |
| CN107208107B (zh) | 2014-12-23 | 2021-07-09 | 伊利亚制药公司 | 伤口愈合的方法 |
| EP3295173B1 (en) * | 2015-05-10 | 2025-11-05 | Ventana Medical Systems, Inc. | Compositions and methods for simultaneous inactivation of alkaline phosphatase and peroxidase enzymes during automated multiplex tissue staining assays |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3919065B9 (en) | 2016-01-14 | 2024-01-24 | Intrexon Actobiotics NV | Compositions and methods for the treatment of type 1 diabetes |
| CN118813511A (zh) * | 2016-09-02 | 2024-10-22 | 英特瑞克斯顿阿克图比奥帝克斯有限公司 | 稳定表达il-10和胰岛素的遗传修饰的细菌 |
| KR102469701B1 (ko) | 2016-09-13 | 2022-11-22 | 인트랙슨 액토바이오틱스 엔.브이. | 점막부착성 미생물 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| GB201906775D0 (en) * | 2019-05-14 | 2019-06-26 | Res & Innovation Uk | Synthetic genome |
| AU2020356592A1 (en) | 2019-09-27 | 2022-04-07 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Treatment of celiac disease |
| WO2024003873A1 (en) | 2022-06-30 | 2024-01-04 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Single variable domain antibodies against tumor necrosis factor-alpha |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB227835A (en) | 1924-01-15 | 1925-04-09 | Harry Odell | Improvements in feeding mechanism for embossing and other printing presses |
| JPS58116498A (ja) | 1981-12-28 | 1983-07-11 | Takeda Chem Ind Ltd | Ｉｌ‐２をコードする新規伝令ｒｎａの製造法 |
| DE3377363D1 (en) | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4752585A (en) | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
| JPH01196296A (ja) * | 1988-01-29 | 1989-08-08 | Toray Ind Inc | 動物細胞用発現ベクター |
| US4919918A (en) | 1988-03-14 | 1990-04-24 | Spectrum Consumer Products Co., Inc. | Non-alcoholic mouthwash |
| US5972685A (en) | 1988-07-21 | 1999-10-26 | Iowa State University Research Foundation, Inc. | Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration |
| GB9006400D0 (en) | 1990-03-22 | 1990-05-23 | Ciba Geigy Ag | Bacterial vectors |
| CA2104104A1 (en) | 1991-02-14 | 1992-09-03 | Daniel K. Podolsky | Intestinal trefoil proteins |
| US6221840B1 (en) | 1991-02-14 | 2001-04-24 | The General Hospital Corporation | Intestinal trefoil proteins |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| GB9126306D0 (en) | 1991-12-11 | 1992-02-12 | Unilever Plc | Mouthwash compositions |
| WO1993017117A1 (en) | 1992-02-27 | 1993-09-02 | Lynxvale Limited | Heterologous gene expression in lactococcus, and the expression products therefrom |
| US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
| EP0569604A1 (en) | 1992-04-07 | 1993-11-18 | Societe Des Produits Nestle S.A. | Integrative gene-expression in Streptococcus salivarius ssp.thermophilus |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US5700782A (en) | 1993-05-28 | 1997-12-23 | Abbott Laboratories | Enteral nutritional product |
| WO1996032486A1 (en) | 1995-04-11 | 1996-10-17 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface |
| US5695746A (en) | 1995-07-28 | 1997-12-09 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Liquid dentifrice with mouthwash fresh taste |
| GB9521568D0 (en) | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
| WO1997026855A1 (en) | 1996-01-24 | 1997-07-31 | Warner-Lambert Company | Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems |
| GB9611364D0 (en) | 1996-05-31 | 1996-08-07 | Smithkline Beecham Plc | Composition |
| US5993785A (en) | 1996-09-18 | 1999-11-30 | Erling Johansen | Mouthwash compositions |
| US5869118A (en) | 1996-11-13 | 1999-02-09 | Abbott Laboratories | Gellan gum to improve physical stability of liquid nutritional products |
| US6171611B1 (en) | 1997-11-12 | 2001-01-09 | Dante J. Picciano | Iodine-containing nasal moisturizing saline and mouthwash solutions |
| US5897872A (en) | 1997-11-12 | 1999-04-27 | Picciano; Dante J. | Iodine-containing nasal moisturizing saline solution |
| ES2234306T3 (es) | 1998-09-28 | 2005-06-16 | Warner-Lambert Company Llc | Administracion enterica y via colon usando capsulas de hpmc. |
| WO2000022909A2 (en) | 1998-10-19 | 2000-04-27 | Biotech Australia Pty. Limited | Systems for oral delivery |
| EP1123314B1 (en) | 1998-10-20 | 2004-02-18 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Use of a cytokine-producing lactococcus strain to treat colitis |
| US6929931B1 (en) | 1999-06-30 | 2005-08-16 | Nestec S.A. | Expression contructs using Lactobacillus delbrueckii subsp. lactis lac repressor protein and its lac repressor binding site, microorganisms and methods thereof |
| PT1739178E (pt) | 1999-07-05 | 2010-11-17 | Actogenix Nv | Libertação de péptidos trifólios |
| AU2001238582A1 (en) * | 2000-02-24 | 2001-09-03 | Siga Pharmaceuticals, Inc | Intergenic and intragenic integration sites for foreign gene expression in recombinant s. gordonii strains |
| US7029842B2 (en) * | 2000-04-07 | 2006-04-18 | Novozymes A/S | Signal sequence trapping |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| ES2266515T3 (es) | 2001-05-03 | 2007-03-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Cepa de lactococcus con autocontencion. |
| EP1319410A1 (en) * | 2001-12-11 | 2003-06-18 | Société des Produits Nestlé S.A. | Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| MXPA05001520A (es) | 2002-07-08 | 2005-05-05 | Joe S Wilkins Jr | Formulaciones antibacteriales. |
| WO2004046346A2 (en) | 2002-11-15 | 2004-06-03 | Vib Vzw | Self-containing lactobacillus strain |
| MXPA05008131A (es) | 2003-01-31 | 2005-10-05 | Univ Pennsylvania | Metodos para la modulacion de una respuesta inflamatoria. |
| EP1493816A1 (en) * | 2003-07-02 | 2005-01-05 | Friesland Brands B.V. | Methods and means for regulating gene expression |
| US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| WO2005071088A2 (en) * | 2003-12-24 | 2005-08-04 | Cerus Corporation | Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof |
| US7842289B2 (en) * | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
| JP2007527242A (ja) | 2004-03-05 | 2007-09-27 | カイロン コーポレーション | 治療剤の患者耐容性を予測するためのインビトロ試験システム |
| US7495092B2 (en) * | 2005-01-14 | 2009-02-24 | North Carolina State University | Compositions comprising promoter sequences and methods of use |
| US7764366B2 (en) | 2006-07-11 | 2010-07-27 | Besi North America, Inc. | Robotic die sorter with optical inspection system |
| JP2009544679A (ja) * | 2006-07-25 | 2009-12-17 | ザ ユニヴァーシティー コート オブ ザ ユニヴァーシティー オブ ダンディー | 異常な細胞増殖に関連する疾患の治療におけるレチノイド及び小分子のＮｒｆ２アンタゴニストとしての使用 |
| KR101557509B1 (ko) * | 2007-01-12 | 2015-10-06 | 액토제닉스 엔.브이. | 락토코커스 프로모터 및 그것의 용도 |
| KR101821417B1 (ko) | 2009-04-30 | 2018-01-23 | 인트랙슨 액토바이오틱스 엔.브이. | 유산균의 냉동건조에 사용하기 위한 냉동보호제 |
| PE20181077A1 (es) | 2011-02-10 | 2018-07-05 | Roche Glycart Ag | Polipeptidos interleuquina-2-mutantes |
| US9669071B2 (en) | 2011-03-11 | 2017-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for stimulating T lymphocytes with IL-2 |
| DK2714912T3 (en) | 2011-06-01 | 2018-08-13 | Intrexon Actobiotics Nv | POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA |
| JP2014526472A (ja) | 2011-09-08 | 2014-10-06 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 免疫応答を調節するための材料および方法 |
| EP3919065B9 (en) | 2016-01-14 | 2024-01-24 | Intrexon Actobiotics NV | Compositions and methods for the treatment of type 1 diabetes |
-
2012
- 2012-06-01 DK DK12729396.7T patent/DK2714912T3/en active
- 2012-06-01 RU RU2018102374A patent/RU2766157C2/ru active
- 2012-06-01 CN CN201280026763.2A patent/CN103562390B/zh not_active Expired - Fee Related
- 2012-06-01 WO PCT/EP2012/060431 patent/WO2012164083A1/en not_active Ceased
- 2012-06-01 EP EP18163611.9A patent/EP3360967B1/en active Active
- 2012-06-01 CN CN201710467009.7A patent/CN107267546B/zh not_active Expired - Fee Related
- 2012-06-01 KR KR1020137033153A patent/KR102066292B1/ko not_active Expired - Fee Related
- 2012-06-01 EP EP12729396.7A patent/EP2714912B1/en active Active
- 2012-06-01 AU AU2012264589A patent/AU2012264589B2/en not_active Ceased
- 2012-06-01 CA CA3136084A patent/CA3136084A1/en not_active Abandoned
- 2012-06-01 JP JP2014513212A patent/JP6175428B2/ja active Active
- 2012-06-01 RU RU2013157300A patent/RU2644346C2/ru active
- 2012-06-01 HU HUE12729396A patent/HUE039577T2/hu unknown
- 2012-06-01 CA CA2837634A patent/CA2837634C/en active Active
- 2012-06-01 ES ES12729396.7T patent/ES2676877T3/es active Active
- 2012-06-01 BR BR112013030824A patent/BR112013030824A8/pt not_active IP Right Cessation
- 2012-06-01 US US14/122,545 patent/US9920324B2/en active Active
-
2017
- 2017-05-09 JP JP2017093388A patent/JP6867866B2/ja active Active
- 2017-05-16 AU AU2017203281A patent/AU2017203281B2/en not_active Ceased
-
2018
- 2018-02-15 US US15/897,427 patent/US10988770B2/en active Active
-
2020
- 2020-12-04 US US17/112,611 patent/US20210163961A1/en not_active Abandoned
-
2021
- 2021-02-02 JP JP2021015026A patent/JP2021097671A/ja active Pending